Guggenheim notes that Judge Maryellen Noreika denied in part Geneoscopy’s motion to dismiss, which means the District of Delaware Court will now proceed with the patent infringement lawsuit regarding patent ‘781. The firm, which notes that Exact Sciences filed suit in 2023 alleging infringement of U.S. Patent No. 11,634,781 based on Geneoscopy’s unapproved ColoSense product, adds that on May 15 Exact filed a second complaint against Geneoscopy regarding patent ‘746, which relates to the same novel sample collection technologies as patent ‘781. The firm, which reminds investors that an Inter Partes Review is also underway and expects a decision sometime in July on whether the PTO will institute a review, has a Buy rating on Exact Sciences shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target lowered to $80 from $85 at BTIG
- Exact Sciences price target lowered to $80 from $100 at Citi
- Exact Sciences price target lowered to $85 from $90 at Canaccord
- Exact Sciences backs FY24 revenue view of $2.81B-$2.85B, consensus $2.83B
- Exact Sciences reports Q1 EPS (60c), consensus (47c)